Commercial architecture for clinical technology, built by operators
It's that complex, and it's that simple. When clinical technology works but revenue doesn't follow, the problem is rarely the product. It is the commercial architecture around it: who buys, who pays, what the evidence must prove, and how the first ten contracts become the next hundred. Having commercialised health technology into public health systems and hospital groups across the UK, India and Brazil, we know that architecture looks different in every market, and we build it accordingly.
We help you discover and define what digital and clinical AI can deliver against your business objectives. From identifying where the deals actually die to designing pricing, evidence and reimbursement pathways, we build commercialisation plans that are readily actionable, because we have run them ourselves. Typical work includes go-to-market design, buyer and payer mapping, pricing strategy, evidence-to-revenue planning, and commercial narratives for boards and investors.
We think market first, always. Through an advisory-network mandate on the IFC's flagship TechEmerge programme, we helped match international health technology companies with Indian and Brazilian health providers at scale; the same market-first method now drives our work across Europe, the Gulf and South Asia. We prioritise geographies, navigate local regulation and reimbursement, match you with the buyers and distributors who matter, and design pilots with conversion criteria built in. Our work isn't about planting flags. It's about contracts that renew.
Placing Health Innovation Into Emerging Markets | Case Study
For healthcare investors, from private equity to development finance institutions, we deliver commercial and impact diligence that reads like an operator wrote it, and portfolio work that survives contact with the sales pipeline. Our impact due diligence follows GIIN-aligned standards and recognised frameworks such as Imperial College London's Healthcare Impact Framework. From commercial due diligence and investment readiness to organisational design and growth mandates, we sit inside the work rather than describing it from outside. Our principal has held senior operating roles at two companies that were subsequently acquired; we know what value creation looks like from within.
Two Exits as a Senior Operator | Track Record
The work doesn't end for us when the first contracts sign. We keep a keen eye on the commercial KPIs we've identified together, adoption, renewal, expansion, and build the playbooks, hiring plans and partner structures that let the engine run after we leave. Success is us becoming unnecessary.
Discuss a growth mandate | Contact
Three ways to start. Each is a fixed-fee, two-to-three-week engagement with a defined deliverable, designed to answer one hard question before you commit to more.
The commissioning map has been redrawn: ICBs have consolidated from forty-two to thirty-six, further mergers towards roughly twenty-six are expected from 2027, and legislation to absorb NHS England into the department is before Parliament. We remap your pipeline to the new landscape, name the decision units that will matter in 2027, and re-sequence your targets. Delivered through stakeholder interviews and pipeline review, with an executive readout and a re-sequenced account plan.
The EU AI Act timetable now varies by system category and product status, and clinical technologies may also fall under MDR or IVDR. Legal advisers determine conformity; we identify the requirements and dates relevant to your product, then translate them into commercial consequences: market sequencing, pricing, evidence strategy, entry timing and how acquirers will diligence your exposure. Delivered through document review and market analysis, with an executive readout and a sequencing decision memo.
For products already in market that aren't growing. We sit in your pipeline, interview the deals that died, and return a diagnosis of where adoption actually stalls, workflow, evidence, pricing or procurement, with a re-architected plan. Delivered through pipeline interviews and loss analysis, with an executive readout and a sequenced commercial plan.
Tell us where the deals are dying. We will tell you, honestly, whether we can help and what it would take.
Contact UsRegistered Office
14/2E Docklands Business Centre
10-16 Tiller Road, London E14 8PX
Fifteen years of delivery in India,
including the IFC TechEmerge
programme from New Delhi
Market entry and government
engagement across the Gulf
through a partner network
Programme experience across
the United States, Brazil
and multilateral institutions